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Possible involvement of PDGF-like growth factors in autocrine
stimulation of cell growth
C.-H. Heldin', A. Hammacher1, A. Ostman', C. Betsholtz2
& B. Westermark2
'Ludwig Institutefor Cancer Research, Box 595, Biomedical
Center, S-752 23 Uppsala and 2Department ofPathology,
University Hospital, S-751 85 Uppsala, Sweden.
Platelet-derived growth factor (PDGF), is a dimer of two
polypeptide chains, A and B. Examples have been found of
A homodimers (e.g. a factor secreted by a human osteo-
sarcoma cell line), B homodimers (e.g. the transforming
product of simian sarcoma virus) and AB heterodimers (e.g.
PDGF purified from human platelets). The frequent
expressions of PDGF-like growth factors in normal, as well
as transformed, cells suggest that such factors have roles in
autocrine and paracrine stimulation of cell growth. For
instance out of 23 investigated human glioma cell lines, 23
and 16 expressed mRNA for the A chain and the B chain,
respectively. PDGF-like factors secreted by one of these'
glioma cell lines were purified and characterized. Two
different PDGF-like factors were resolved by HPLC reverse
phase; one was identified as an A chain homodimer, whereas
the other contained at least one B chain. All dimeric forms
of PDGF binds to human fibroblasts and competes, at least
partially, with 125I-PDGF for binding. However, A homo-
dimers have a lower mitogenic activity compared to B chain
containing dimers. This finding, in combination with the
observation that A chain homodimers remain preferentially
cell associated suggests that different PDGF dimers have
different functions in vivo.
Transforming growth factors and cancer
H.L. Moses
Department ofCell Biology, Vanderbilt University School of
Medicine, Nashville, Tennessee 37232, USA.
Two types of transforming growth factors (TGF) have been
purified and well characterized, TGFa and TGF,B. TGFx is a
5.6kD single chain EGF-related molecule that binds to the
EGF receptor and has biological effects very similar to those
of EGF; it is mitogenic for most cell types including normal
epithelial cells. TGF,B is a 25 kD homodimer of 12kD
subunits that has its own specific cell surface receptors.
While growth stimulatory for selected mesenchymal cells,
TGF# inhibits proliferation of most cell types including
*Enquiries to the BACR Secretariat, c/o Institute of Biology, 20
Queensberry Place, London, SW7 20Z, UK.
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normal epithelial cells. Using cultured skin keratinocytes as a
model system for normal epithelial cells, the production of
and response to TGFa and TGFf has been examined along
with potential mechanisms of growth inhibition by TGFfl.
The keratinocytes are stimulated to proliferate by EGF and
TGFa. TGFa is produced by adult and neonatal skin
keratinocytes, and this production is autoregulated. TGF#,
on the other hand, is a potent inhibitor of keratinocyte
proliferation. The mechanism of growth inhibition by TGFfl
appears to involve selective inhibition of expression of
growth factor inducible genes necessary for cell proliferation.
The keratinocytes also synthesize and release TGF#, but in a
latent form; the major regulatory step in TGFP action may
be at the level of activation of the latent form. Normal
autocrine stimulation by TGFa and autocrine inhibition by
TGFf is implied and changes in this autocrine regulation
may be important in neoplastic transformation of epithelial
cells. Both increased autocrine stimulation by endogenous
TGFa and decreased inhibition by TGF,B could lead to an
increased proliferative potential.
Transforming growth factor-beta: A possible link between the
processes of inflammation/repair and carcinogenesis
A.B. Roberts & M.B. Sporn
Laboratory ofChemoprevention, National Cancer Institute,
Bethesda, MD 20892, USA.
Transforming growth factor-beta (TGF-beta) is a 25,000
dalton disulfide-linked homodimeric peptide found princi-
pally in platelets and bone, suggesting a role in tissue repair
and remodeling. It controls a broad spectrum of biological
responses including cell growth, cell differentiation, other cell
functions (for a review, see Sporn et al., J. Cell Biol., 105,
1039, 1987). TGF-beta is secreted by and acts on many of
the cells common to the stromal elements of a tumor and the
granulation tissue of a healing wound, namely inflammatory
cells, endothelial cells, and fibroblasts. Thus at femtomolar
concentrations, TGF-beta is chemotactic for both macro-
phages and fibroblasts, while at higher concentrations, it
activates macrophages to secrete mitogens such as IL-1 and
fibroblasts to secrete connective tissue proteins such proteo-
glycans, fibronectin, and types I, III, and V collagen. The
accumulation of matrix proteins is further augmented by a
second TGF-beta-dependent mechanism in which the peptide
decreases cellular secretion of matrix-degrading proteases
and increases synthesis of protease inhibitors. The acute
release of TGF-beta from platelets which initiates the healing
response is replaced in tumorigenic development by
continuous aberrant secretion of the peptide by the tumour
cells. It is the ability of the tumour to perpetuate the
normally self-limiting healing response that distinguishes
these two processes. The central role of TGF-beta in both
processes provides the mechanistic link between them.
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Peptides of the bombesin family: Receptors and mitogenic
actions
E. Rozengurt, I. Zachary, J. Sinnett-Smith, E. Nanberg,
P.J. Woll & J. Millar
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
Regulatory peptides which act in an autocrine or paracrine
fashion on adjacent cells are increasingly implicated in the
control of cell proliferation. The amphibian tetradecapeptide
bombesin and mammalian peptides structurally related to
bombesin including gastrin-releasing peptide (GRP) are
potent mitogens for Swiss 3T3 cells. These peptides bind to
high-affinity cell-surface receptors which are distinct from
those of other mitogens for these cells. A surface protein in
Swiss 3T3 cells with apparent Mr 75000-85000 has been
identified by chemical cross-linking as a putative component
for the bombesin/GRP receptor. The affinity labelled protein
binds to wheat germ lectin-sepharose columns from which it
can be eluted by N-acetyl-D-glucosamine. Receptor bound
1251-GRP is internalised and extensively degraded by these
cells. However in contrast to other growth factors, peptides
of the bombesin family do not cause down-regulation of
their specific cell-surface receptors. Following binding the
peptides elicit a complex array of early biological responses
including: (a) phosphorylation of the 80K cellular protein,
which reflects the activation of protein kinase C in intact
3T3 cells; (b) phosphoinositide breakdown and mobilisation
of Ca2+ from an intracellular store, which leads to a
transient increase in the concentration of cytosolic Ca2+ and
Ca2+ efflux; (c) stimulation of activity of the Na+/H+
antiport; (d) transmodulation of EGF-receptor affinity; (e)
enhancement of cAMP accumulation; and (f) increase in the
expression of the cellular oncogenes c-fos and c-myc. The
peptides of the bombesin family not only provide a novel
and valuable model for the elucidation of the signal trans-
duction pathways underlying cellular proliferation but also
play a role as autocrine growth factors for human small cell
lung cancer cells.
The 8th Gordon Hamilton-Fairley Memorial
Lecture
The role of growth factors in health and disease
R. Ross
Department ofPathology, University of Washington, Seattle,
WA 98195, USA.
Many of the established growth factors appear to be trophic
for particular cell types, such as mesenchymal connective
tissue-forming cells (PDGF), endothelial cells (FGF),
epithelial cells (EGF/TGFa), and lymphocytes (interleukins).
Numerous different cell types, including most transformed
cells, are capable of forming one or more growth factors or
their homologues. Several diploid cells also can form
different growth factors, including monocyte/macrophages
(PDGF, FGF, TGFa, IL-1), endothelium (PDGF, F-GF,
IL-1), keratinocytes (TGFa), and smooth muscle (PDGF).
Growth factor function may be dependent upon cellular
interactions and may result in the release of substances by
cells that lead to a cascade of events culminating in cellular
responses ranging from chemotaxis and increased cell
contractility to DNA synthesis and cell replication. Tumour
growth may result from autocrine stimulation by growth
factors such as PDGF, whereas factors such as PDGF may
also act in a paracrine fashion to induce fibroproliferative
responses such as desmoplasia, which often accompanies
different neoplasms. Connective tissue proliferation can also
occur as a result of growth factor release from macrophages
involved in the process of inflammation and wound repair.
Thus these factors may play critical roles in cell
proliferation, which is the hallmark of diseases that include
atherosclerosis, rheumatoid arthritis, pulmonary fibrosis, and
neoplasia.
The interleukins: Lymphocytic growth and differentiation
factors
C.S. Henney
Immunex Corp., Seattle, WA 98101, USA.
The interleukins are a group of protein hormones produced
by lymphocytes and macrophages which control the growth,
differentiation and activation of cells of the immune system.
The interleukin 'family' is grouped only by its biological
effects; there is no interleukin gene 'family', nor do the
proteins encoded by interleukin genes share structural
homology.
To date, five interleukin genes have been cloned, and their
products, interleukins 1 through 5, have been characterized
chemically and biologically. One of these proteins,
interleukin-2, has been assessed clinically as an immuno-
restorative and immunopotentiating agent; clinical testing of
interleukins 1, 3 and 4 will begin within the next year.
The interrelated biological effects of the interleukins will
be discussed with a particular focus on the clinical potential
of these proteins in the treatment of immune dysfunction.
Growth factors in myelopoiesis: What role for stromal cells?
T.M. Dexter
Christie Hospital and Holt Radium Institute, Manchester
M20 9BX, UK.
Human angiogenin, an organogenic protein
B.L. Vallee
Centerfor Biochemical and Biophysical Sciences and
Medicine, Harvard Medical School, Boston, Massachusetts,
USA.
The first human tumour derived protein with in vivo
angiogenic activity to be obtained in pure form has been
isolated from serum-free supernatants of an established
human adenocarcinoma cell line (HT-29) and named angio-
genin. Biological activity of angiogenin was monitored
throughout purification by using the chick embryo chorio-
allantoic membrane assay. It displays activity in this system
with as little as 35fmol per egg, and only 3.5pmol is
required to induce extensive blood vessel growth in the
rabbit cornea. The amino acid sequence and disulfide bond
pairing of human tumour derived angiogenin have been
determined by conventional sequencing techniques adapted
and applied to nanomole and subnanomole levels of
material. Angiogenin obtained from such conditioned media
is a single-chain protein consisting of 123 amino acids
(I.P. >9.5) and molecular weight - 14,400.
The sequence is homologous to that of the pancreatic
ribonucleases with 35% identity and many additional
residues are replaced conservatively. Similarities are
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12, Lys-41, and His-I 19 of ribonuclease which are conserved
as are three of the four disulfide bonds.
This unexpected homology to ribonuclease A suggests
novel approaches to the investigation of the biological
process of angiogenesis and may be relevant to the evolution
oforganogenic molecules and their physiological implications.
Subversion of growth factor signals in control of abnormal cell
proliferation
M.D. Waterfield
Ludwig Institutefor Cancer Research, Middlesex Hospitall
University College Branch, London WJP 8BT, UK.
The search for mechanisms which explain the molecular
basis of signals which generate the abnormal growth
properties of transformed cells in vitro and cancer cells in
vivo has in the last few years, focused on pathways involved
in growth factor signal transduction. Through the ability to
characterise, the structure and function of growth factors
and their receptors linked to progress made in understanding
oncogenes, tumour promoters and cell physiology, major
conceptual advances have occurred. Thus, through abnormal
production of a growth factor what may be an intra or
extracellular autocrine control loop can be established.
Subversion can occur by activation of a cellular gene or
through generation of an oncogene. An alternative
mechanism may be to obviate the need for the factor, for
example by generation of an altered receptor which may
mimic the signal of ligand stimulated receptor or through the
action of a tumour promoter mimic an activator and activate
second messenger generation. In some cases, an intracellular
signal may be generated to bypass the entire receptor system.
Abstracts of proffered papers
The prognostic value of immunohistochemical assessment of
c-erbB-2 amplification in human breast tumours
D.M. Barnes', G.A. Lammie2, W.L. Gullick3 & R.R. Millis'
Departments of 1Clinical Oncology, 2Clinical Microscopy,
Guy's Hospital, London SE], 3Institute ofCancer Research,
London SW3, UK.
There is increasing interest in the role of the c-erbB-2
oncogene in the pathogenesis of human breast cancer. An
immunohistochemical study has been carried out using a
polyclonal antibody (21N) raised to a peptide consisting of
residues 1243-1255 of the open reading frame of the c-erbB-2
molecule. (Gullick et al., Int. J. Cancer, 40, 246, 1987).
Formalin-fixed paraffin embedded sections of 150 primary
breast tumours from patients followed up for a period of 10-
12 years, were studied. Staining was carried out with the
primary antibody at dilutions ranging from 1/20 to 1/400,
using the avidin-biotin technique. Specificity was confirmed
by the elimination of staining following pre-incubation of the
primary antibody with the immunising peptide. Due to
heterogeneity of staining, several scoring systems were
devised, reflecting patterns of staining intensity and
distribution. Using each system the staining for the tumours
was graded as: (a) negative, (b) weak, (c) moderately strong,
or (d) very strong. The results were then compared with
established prognostic parameters (nodal status, histological
pattern, grade, receptor status) as well as with clinical
outcome.
Studies such as this with the 21N antibody will hopefully
clarify the role of c-erbB-2 in the aetiology of breast cancer,
and its value as a prognostic marker.
Oestrogen receptor, epidermal growth factor (EGF) receptors
and EGF levels in breast tumours
D.G. Godfrey1, C. Porteous2, W.D. George2, I. Pragnell3,
S. Cowan1 & R.E. Leake'
Departments of 'Biochemistry and 2Surgery, University of
Glasgow, Glasgow G12 8QQ and 3Beatson Institute, UK.
The presence or absence of epidermal growth factor receptor
(EGF-R), and oestrogen receptor (E-R) was determined in
156 patients. The amount of EGF extractable. from the tissue
was measured when sufficient tissue permitted. E-R was
measured using the dextran coated charcoal seven point
competition assay which is used routinely in our EORTC
studies. EGF-R was detected using a 2 point radioreceptor
assay and EGF was measured by RIA with an 'in house'
rabbit polyclonal anti-EGF antibody.
The Table demonstrates the relationship between EGF-R
and E-R and EGF. The x2 test indicated no significant
correlation between any of the parameters. These findings,
however, differ from those of Sainsbury et al. (Lancet, i, 364,
1985). Additionally age and lymph node involvement were
found to have no bearing on EGF-R status or EGF content.
Although both of the ER groups have lower levels of EGF,
the prognostic relevance of this, together with the other data
remains to be established.
EGF (ngml-')
Total (n= 156)
ER+/EGFR+
ER-/EGFR+
ER+/EGFR-
ER-/EGFR-
34 (22%)
46 (29%)
31 (20%)
45 (29%)
<1 >1
9
13
9
17
8
2
5
6
Epidermal growth factor receptor (EGF-R) expression in
small cell lung cancer tumours
F.G. Hay1, R. Milroy2, L.W. Adams', S.G. Allan1,
M.R. Adamson3 & R.C.F. Leonard'
'Edinburgh Medical Oncology Unit, Western General Hospital,
Edinburgh, 2CRC Department ofClinical Oncology, Glasgow,
and 3Department ofPathology, Royal Infirmary, Glasgow,
UK.
Recent studies of expression of epidermal growth factor
receptor (EGF-R) in human lung cancer suggest that small
cell lung cancer (SCLC) tumours do not express this receptor
(Cerny et al., Br. J. Cancer, 54, 265, 1986). Our preliminary
study of 38 tissue sections from patients with SCLC stained
by a standard PAP method, using monoclonal antibody
EGF-RF4 against a synthetic peptide from the cytoplasmic
domain of the EGF-R, yielded positive staining in 4
instances. The samples included 31 bronchial biopsies (2/31
positive) and 7 metastatic lesions (2/7 positive). Observations
were extended to a second series of 35 tissue sections of
SCLC patients using monoclonal antibody EGF-RD1O in
addition to EGF-RF4 (Gullick et al., Cancer Res., 46, 285,
1986), also against the cytoplasmic domain of EGF-R. In
this series 9/27 primary bronchial biopsies were positive with
both antibodies, while a further 6 were positive with EGF-
RF4 alone; 3/6 secondary deposits were positive with both.222 JOINT MEETING OF THE BACR, THE CRC AND THE ICRF
The degree of staining varied from isolated foci of positive
cells to strong positivity in 20-50% of tumour cells. An
association was noted between EGF-RF4 positivity and
reduced survival for patients in the first series studied, with a
means survival time of 5 months in patients having EGF-
RF4 positive biopsies compared with 10 months in those
which were negative.
Epidermal growth factor receptor and cellular DNA content in
non-small cell lung cancer: Clinical and biological significance
H. Dazzi1, P.S. Hasleton2, T.E. Roberts2 & N. Thatcher'
Department ofPulmonary Oncology and Pathology,
Wythenshawe Hospital, Manchester, UK.
The epidermal growth factor receptor (EGF-R) is ubiquitous
in man with the exception of the circulating cells of the
haemopoietic system. Overexpression of EGF-R has been
reported in epidermal carcinoma and various brain tumours.
So far only in breast cancer has the overexpression of the
EGF-R correlated with poor prognosis.
In a retrospective study the expression of EGF-R as
detected by immunohistochemistry on paraffin embedded
sections has been compared with aneuploidy, histological
type, tumour differentiation and survival in 119 patients with
non-small cell lung cancer (NSCLC).
Eighty-six per cent of squamous cell carcinomas and
adenocarcinomas expressed EGF-R but 5/6 of the large cell
carcinoma and 10/16 undifferentiated NSCLC expressed also
EGF-R. There was a trend for the less differentiated
squamous or adenocarcinoma to express less EGF-R.
Groups of tumours with variable EGF-R expression did not
show any difference in the proportion of diploid/aneuploid
DNA histograms analysed by flow cytometry. The only
statistically significant correlation (P<0.05) was found in
tumours with very low (10%) or no expression of EGF-R
and multianeuploid tumours and a higher proportion (> 50%)
of cells of well differentiated tumours expressed EGF-R
(P <0.0047).
Epidermal growth factor receptors in four new squamous cell
carcinoma of the cervix cell lines
K.S. Tonkin', M. Berger2, M. Ormerod' & L.R. Kelland'
'Institute of Cancer Research, Clifton Avenue, Sutton, Surrey
SM2 5PX, 2University ofPennsylvania, Philadelphia, USA.
EGF receptors are commonly increased in tumours of
epithelial cell origin and in some this is associated with gene
rearrangement or overexpression. We have evaluated four
new carcinoma of the cervix cell lines for EGFR properties.
Immunocytochemical staining of all four lines using the
EGFR1 monoclonal antibody showed a wide intra- and
inter-line variation in intensity of staining. Flow cytometric
analysis of EGFR1 demonstrated a threefold variation in
staining intensity with different patterns of staining between
the cell lines. We confirm the heterogeneous pattern of
staining using single cell cloned derivatives of one line. Using
all lines and the clones in low and high passage we show a
marginal increase in staining with passage in culture.
Scratchard analysis shows that three lines have 2 x10'
low affinity and 2 x 104 high affinity receptors per cell and
that the fourth line has 7 x 104 low afflnity and 7 x 10' high
affinity receptors per cell. Southern blotting did not reveal
any rearrangement or amplification of the EGFR gene. We
cannot demonstrate any definite mitogenic effect of
exogenously added EGF in culture.
We conclude that there are wide differences in EGFR
expression in carcinoma of the cervix. We find no relation-
ship between EGFR staining ploidy or degree of
differentiation. However, the cell line with the lowest
receptor number has the longest doubling time in vitro. We
demonstrate a potential artefact with increasing EGFR
expression with passage in culture.
Antibody guided diagnosis and therapy of brain gliomas using
radiolabelled monoclonal antibodies against epidermal growth
factor receptor and placental alkaline phosphatase
P. Haralabos, C.G. McKenzie, D. Thomas & A.G. Epenetos
Hammersmith and Maida Vale Hospitals, London, UK.
Twenty-three patients with known or suspected brain
tumours were scanned using 123-iodine labelled monoclonal
antibodies against epidermal growth factor receptor
(EGFR1) and placental alkaline phosphatase (H17E2). Ten
patients were also imaged using a non-specific control
antibody (11.4.1) of the same immunoglobulin subclass.
Successful localisation was achieved in 19/23 patients. The
specificity of targetting was confirmed by comparing imaging
using specific and non-specific antibodies and examining
biopsies after dual antibody administration.
Seven pateints with recurrent grade III or grade IV glioma
who showed good localisation of radiolabelled antibody were
treated with 40-140mCi of 131-iodine labelled antibody
delivered to the tumour area by infusion into the internal
carotid artery. Six patients showed clinical improvement
lasting from 3 months to 2 years. One patient continues in
remission (2 years after therapy), but 5/6 patients who
responded initially, relapsed 6-12 months post therapy and
died. No toxicity was attributable to antibody guided
irradiation.
Targetted irradiation by monoclonal antibody delivered by
arterial infusion of the tumour area may be useful and
should be explored further in randomised studies for the
treatment of brain gliomas resistant to conventional forms of
treatment.
Interferon receptor interaction: A study using monoclonal
antibodies to HuIFN-a
M. Shearer & J. Taylor-Papadimitriou
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
Monoclonal antibodies to HuIFN-c species have been
isolated as tools to study IFN-receptor interaction (Shearer
et al., J. Immunol., 133, 3096, 1984). The antigenic
determinants of 4 of these have been identified using hybrid
and analogue IFNs. Amino acids in the 107-113 region of
HuIFN-ac2 are implicated in the epitopes recognised by three
of the antibodies while the fourth antibody recognises IFNs
with arginine at position 121 (Taylor-Papadimitriou et al., J.
Immunol., 139, 1987, in press). Binding of IFN to its
receptor on human and bovine cells in the presence of excess
concentrations of these four antibodies is inhibited and as
expected the biological activity of IFN is neutralised.
However binding of IFN in the presence of equimolar
concentrations of the antibodies has shown that the 107-121
region of IFN containing the antigenic determinants is
exposed and able to bind Ab when IFN is bound to its
receptor on human cells but not when bound to its receptor
on bovine cells. At equimolar concentrations the antibodies
partially inhibit internalisation of IFN in human cells and
also partially inhibit biological activity. Studies using radio-
labelled antibody to determine receptor levels have shown
that, contrary to the published data, the IFN receptor is
only marginally down regulated in human cells and is in fact
blocked by bound ligand.
These antibodies are being used to follow the fate of the
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Production of transforming growth factors at and p by human
keratinocytes and oral squamous cell carcinoma
M. Partridge' & M. Green2
ICharing Cross Sunley Research Centre, London W6 8LW,
and 2Unilever Research, Colworth House, Sharnbrook,
Bedford MK44 ILQ, UK.
The distribution and intensity of epidermal growth factor
(EGF) receptor expression varies between patients with oral
squamous cell carcinoma (SCC) although there appears to be
no significant correlation between the level of receptor
expression and tumour behaviour. EGF is only one of
several polypeptide growth factors involved in normal cell
proliferation. Another is transforming growth factor-alpha
(TGF-a) which is structurally related to EGF and also binds
to the EGFR.
We have demonstrated production of varying amounts of
TGF-as by oral SCC using Northern blotting and radio-
immunoassay. Tumours which express EGFR may therefore
have enhanced proliferation in response to autocrine or
paracrine production of TGF-a.
TGF-x mRNA and protein were also present in cultured
human keratinocytes. There is increased secretion of TGF-x
by these cells in response to 10ngml-' EGF. Small amounts
of protein were also found in human skin but it is not yet
clear if this TGF-ax is synthesized locally.
TGF-,B mRNA was also seen in keratinocyte cultures and
oral SCC. TGF-f, may therefore also play a role in normal
and malignant cell growth.
Transforming growth factors (TGFs) ca and p in biopsies of
normal and malignant human breast
P.J. Barrett-Lee, M.T. Travers, Y.A. Luqmani & R.C.
Coombes
Ludwig Institutefor Cancer Research, St George's Hospital
Medical School, Cranmer Terrace, London SW17 ORE, UK.
Recent work in vitro has implicated several peptide growth
factors in the growth of breast cancer cells. TGFa and its
receptor, epidermal growth factor receptor (EGF-R), have
been detected in several human breast cell lines. TGFP is a
potent growth stimulator of a variety of mesenchymal cells
including fibroblasts, but its effect on certain breast cancer
cell lines is inhibitory. Much less is known about the
occurrence of these factors in human breast tissues. Forty-six
human breast cancer biopsies and 18 non-malignant breast
samples were analysed for the presence of transcripts for
TGFa and ,B, and EGF-R using human cDNA probes. Dot
blot and northern analysis detected TGFa mRNA of 4.8kb
and 2.2kb in 39% of breast cancer biopsies compared to 22%
of benign samples. The presence of TGFa mRNA was
inversely correlated with the presence of oestrogen receptor
(ER), as determined by conventional methods (P<0.05). In
addition, transcripts for EGF-R were detected in 42% of
carcinomas, and their presence was inversely correlated to
ER (P<0.05). In contrast, all specimens of benign breast
contained significant EGF-R message regardless of ER
status. Production of immunoreactive EGF-R protein was
confirmed in 15 samples of malignant and benign breast,
using a monoclonal antibody (EGF-R1). TGFf mRNA was
in contrast, found in all tissue examined. The levels varied
considerably, but were significantly higher in cancers
compared to benign tissues (P<0.05). Normal human
lymphocytes were also found to contain high levels of the
2.5kb transcript but in 39 malignant breast tumours no
association was found between amounts of TGF,B message
and the degree of lymphocytic invasion assessed on histo-
logical sections. These data suggest a possible autocrine
growth role for TGFs in human breast cancer.
EGF and TGFcc found in macrophages present in human
carcinomas
S. Farmer, D.B. Jones, D. Davies & P. Alexander
CRC Medical Oncology Unit and Department ofPathology,
Southampton General Hospital, Southampton S09 4XY, UK.
Acid extracts prepared from human and mouse carcinomas
were found by ELISA to contain h. and mEGF respectively
as well as TGFa. In frozen sections of colonic and mammary
carcinomas a proportion of cells stained with a monoclonal
antibody (MAB) to h.EGF which does not react with TGFa.
Double staining with MABs identifying macrophages
(CDllc/3.9) and cytokeratin (5.2) showed unequivocally that
in the majority of primary tumours and lymph node
metastases EGF is not found in cytokeratin positive cells but
is present in some but not all of the cells that stain as
macrophages. An MAB to TGEa stained not only all of the
epithelial (cytokeratin positive) cells within many of the
tumours but also some of the macrophages. The same
subpopulation of macrophages appears to contain h.EGF as
well as TGFa. This observation is not due to spurious cross
reactions as the MAB to TGFoa does not recognise h.EGF.
That all macrophages do not contain h.EGF and TGFax is
clearly shown in the spleen in which none of the CDllc
positive cells bind MABs specific for h.EGF or TGFa.
However macrophages present in frozen sections derived
from a variety of granulomatous conditions were strongly
+ve for h.EGF and TGFx. Freshly separated peripheral
blood monocytes stained very weakly or not at all for h.EGF
and TGFcx but were positive with MAB 3.9. However after
culturing for 4h the adherent monocytes became strongly
positive for h.EGF and TGFa. Apparently tissue macro-
phages stemming from recently arrived monocytes contain
h.EGF and TGFa but after a prolonged period of residence
these growth factors are lost. These studies suggest that
macrophages make a significant contribution to the presence
of the EGF class of growth factors within tumours and that
there may be considerable overlap between autocrine and
paracrine stimulation.
Effect of anti-EGF antibody on cell growth in vitro and
tumour growth in vivo
J. Blackler, P. Alexander, S. Farmer & D. Davies
CRC Medical Oncology Unit, Southampton General Hospital,
Southampton S09 4XY, UK.
Antibodies raised in sheep to mouse EGF were used to test
if host derived EGF is required for the progressive growth in
vivo of low numbers of carcinoma cells which contain TGFa
activity but do not make mEGF. ELISA showed that the
antibody cross-reacted weakly with hEGF and TGFa but
did not inhibit hEGF or TGFa induced mitogenesis. However
the IgG inhibited the mintogenic activity of mEGF in a
manner that depended both on the dose of IgG and the
amount of mEGF used.
In vivo anti-tumour activity of the antibody was tested
against a transplanted mammary carcinoma which grows
from 5 x 103 cells i.p. 2.5mg of IgG was given i.p. three times
a week. In the first experiment the mice were killed- at 29
days: 5/5 untreated mice had large omental tumours while in
the treated group 2/5 were tumour free and 3/5 had small
tumours. In the second experiment the mice were followed
for up to 3 months: in the untreated group and the group
receiving control IgG 8/10 died between 40 and 90 days and
2/10 in each group were alive and tumour free at 100 days.
In the group receiving anti-EGF IgG only 3/10 developed a
peritoneal tumour but all died from renal failure between
days 60 and 93. No anti-tumour activity was observed224 JOINT MEETING OF THE BACR, THE CRC AND THE ICRF
against sarcoma cells in a similar experiment. The antibody
reacted in frozen sections with distal tubules in the kidney. In
the serum of mice receiving thrice weekly IgG free antibody
circulated at a concentration which inhibited in vitro mito-
genesis of fibroblasts by 190ng EGFml- . The level of
mEGF in the urine of mice was not reduced suggesting that
urinary EGF does not come from the blood.
Determination of polypeptide growth factors in the urine of
patients with carcinomas
J.W. Sweetenham, D. Davies, J. Blackler & P. Alexander
CRC Medical Oncology Unit, Southampton General Hospital,
Southampton S09 4XY, UK.
Urogastrone (hEGF) in urine was measured by a specific
two-site ELISA which does not detect mEGF or TGFa.
More than 99.99% of the hEGF in urine could be removed
by binding to a monoclonal antibody. Absorbed urines were
analysed for growth factors other than hEGF by competitive
binding to EGF receptors and by mitogenic activity
measured by induction of DNA synthesis in density-inhibited
foreskin fibroblasts under conditions where EGF, TGFa and
PDGF were active but added insulin or transferrin were not.
After absorption, urinary hEGF was eluted from antibody
and after separation by FPLC (anion-exchange) immune-
and receptor-binding activity was found in several fractions,
none of which coincided with the peak from plasmid derived
hEGF produced in E. coli.
The hEGF/creatinine ratio in the urine of untreated
patients with colon and breast cancers (and a small number
with bladder cancer and hypernephroma) was elevated but
within the normal range. The chromatographic profile of
hEGF from the urine of cancer patients could not be
distinguished from that of normals. Following hEGF
absorption, no receptor binding or mitogenic activity could
be detected in whole urine.
As synthetic human TGFoa is readily separable by FPLC
from the hEGF components, urine free of hEGF was
separated by FPLC and the mitogenic activity of the
fractions measured. PDGF and basic fibroblast growth factor
does not bind to the anionic column and would not be
detected.
Mitogenic activity was observed in several fractions from
cancer patients. Some, but not all of this was blocked by an
antibody to EGF receptors which inhibits mitogenicity due
to hEGF, mEGF and TGFa.
Benign thyroid epithelial tumours show escape from IGF-1
dependence for growth
D. Wynford-Thomas, D.W. Williams & E.D. Williams
Cancer Biology Unit, Department ofPathology, University of
Wales College ofMedicine, Cardiff, UK.
We have investigated the proliferative response to growth
factors of normal and neoplastic human thyroid epithelial
(follicular) cells in vitro. Follicles were prepared by
collagenase/dispase digestion from histologically normal
tissue taken from lobectomies performed for non-neoplastic
conditions, and from 6 thyroid adenomas. Follicles were
cultured in suspension or as monolayers in serum-free
RPMI1640 medium and growth responses assessed by 3H-
thymidine incorporation and autoradiographic labelling
index in successive 24h periods after addition of growth
factor(s).
All 6 batches of normal follicles showed no response to
thyrotropin (TSH) or IGF-1 when added singly. However, in
the presence of IGF-1 (1Ongml-1) a clear bell-shaped dose-
response curve to TSH was seen with a 4-5-fold increase in
3H-thymidine incorporation at 0.1 mUml- . In a
representative experiment incorporation at 4-5d increased
from 758+43 cpm (mean of 4 cultures +s.e.) with IGF-1
alone to 3722+63cpm with O.1mUml-1 TSH plus IGF-1.
The corresponding labelling index rose from 4% to 15%.
In contrast, in 5 out of 6 adenomas a response of
equivalent timing and greater than or equal magnitude was
obtained with TSH in the absence of any IGF-1. A
representative adenoma gave a peak increase in 3H
incorporation from a basal value of 1050 +70cpm to 6998+
600cpm with 0.1 mUml1 TSH alone. The labelling index
rose from 9.8% to 33.2%. In the remaining adenoma, a
similar labelling index was observed in the absence of any
added growth factors.
We conclude that escape from the requirement for
exogenous IGF-1 is an early step in the development of
human thyroid follicular cell neoplasms. We are currently
investigating the possibility that this is due to an autocrine
mechanism.
Multihormonal regulation of prostatic growth responses
T.D. France, M.E.A. Phillips, C.L. Eaton & P. Davies
Tenovus Institutefor Cancer Research, Heath Park, Cardiff
CF4 4XX, UK.
Prostate epithelial cells are considered a paradigm of
androgen dependency. However, their growth can be
influenced by many other steroid and peptide agents. As
adenocarcinoma of the prostate, which arises in epithelial
cells, inevitably progresses to androgen-independence these
other agents and their mechanisms may be legitimate and
more fruitful targets of therapy.
Various prostatic normal and neoplastic cell lines show
growth dependence on glucocorticoids, epidermal growth
factor (EGF) and insulin. As a corollary, ligand binding
assays have detected receptor sites for dexamethasone, EGF
and insulin-like growth factor (IGF)-I. Receptors for EGF
and IGF-I have also been detected in human prostate
specimens. Significant differences in receptor site concen-
tration and affinity have been observed between hyper-
trophic (BPH) and carcinomatous prostate.
Protooncogene expression in prostate cells has been
investigated by quantitative dot (slot)-blot hybridization
analysis of RNA. Compared to BPH, c-myc expression was
elevated in all grades of carcinoma, correlating well with
EGF-binding capacity, and c-H-ras expression became
increasingly elevated with loss of glandular differentiation
and appearance of secondary binding sites for IGF-I.
Expression of c-fos did not change relevant to pathology, but
correlated significantly with androgen receptor content.
These circumstantial correlations were substantiated using
cell lines.
Prostate growth is under the control of several regulatory
agents and aberrant growth can be linked to alterations in
the capacity to respond and mechanisms of response to these
agents.
Role of protein kinase C activation and c-fos gene expression
in growth control of a murine macrophage tumour
N.T. Goode & I.R. Hart
Imperial Cancer Research Fund Laboratories, Lincoln's Inn
Fields, London WC2A 3PX, UK.
Treatment of cells of the murine reticulum cell sarcoma line,
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had markedly different effects in terms of proliferative
response evoked but produced very similar changes in
magnitude and kinetics of c-fos expression. Thus, the tumour
promoters mezerein and the phorbol esters 12-0-tetra-
decanoyl phorbol-13-acetate (TPA) and phorbol 12,13-
dibutyrate (PDBu) [all at 50ngml-1] exerted a strong anti-
proliferative effect, whereas the non-promoting phorbol ester
analogue 4a-phorbol 12,13-didecanoate (4acPD) had no effect
on this parameter. Analogues of the natural PKC activator
diacylglycerol used at 20/,igml-1 did not affect proliferation
(1,2-Dioctanoyl Glycerol [DiC8]) or were mitogenic (1-
Oleoyl-2-acetyl glycerol [OAG]). However, all PKC
activators evoked a rapid and transient increase in c-fos gene
expression as measured by Northern blotting of poly(A')
mRNA with maximum levels of steady state mRNA obtained
15-30min after initiation of treatment and a decline to
resting levels 2h later.
These results, obtained in a single cell line, show that the
induction of c-fos gene expression following PKC activation
may be a general signal associated with changes in
proliferative status but is not deterministic of that change.
This hypothesis is in agreement with the observation of
induction of c-fos gene expression both when fibroblasts and
lymphocytes are induced to enter Gl from GO by mitogenic
growth factors and when myelomenocytic cells are differen-
tiated with concommitant cessation of cell proliferation. That
divergent proliferative responses may be a consequence of
altered expression of PKC isozymes has been investigated
using cDNA probes to PKC-oa, ,B and y on Northern
analysis. Similarly, the possibility that changes in cell growth
responses may reflect temporal differences in PKC down-
regulation has been examined in the M5076 line and the
results of these studies will be presented and discussed in the
context of regulatory signals and obligatory events in growth
control.
Phosphorylation of the calcium/phospholipid-dependent binding
protein, p68, in human syncytiotrophoblast plasma membranes
P.D. Webb & P. Kenton
Department ofImmunology, University ofLiverpool, PO Box
149, Liverpool, UK.
Human placental syncytiotrophoblast plasma membrane
forms the interface with maternal blood. It is rich in EGF
and insulin receptors and expresses the oncotrophoblast
antigen placental-type alkaline phosphatase. PLAP is
associated with phosphatidylinositol (Ptdlns) and can be
released from these membranes and tumour cells with
exogenous Ptdlns-specific phospholipase C (Ptdlns-PLC).
We have also shown a 'family' of calcium-dependent
proteins bind to the trophoblast submembraneous cyto-
skeleton. These include lipocortins I and II, phosphorylated
on tyrosine after EGF treatment, a non-phosphorylated
34kD protein, probably endonexin, and a 68 kD component
not previously shown to be phosphorylated. From Western
blots this protein is related to p68, the calcium-dependent
binding protein isolated from human lymphocytes. P68 was
found to be a major phosphorylated component of
trophoblast membranes. It was principally phosphorylated
on serine with trace amounts of tyrosine. On incubation of
the membranes with EGF there was a time-dependent
increase in p68 tyrosine phosphorylation. The phorbol ester,
TPA, also stimulated p68 phosphorylation but only at
10nm or less. At higher concentrations phosphorylation of
p68 decreased. Addition of Ptdlns-PLC, at concentrations
which cleave PLAP from the membranes, also reduced, in
a dose-dependent manner, p68 phosphorylation. Since
Diacylglycerol generation may accompany this Ptdlns-PLC
release of PLAP it raises the possibility that the normal
mechanism in release of soluble PLAP into the circulation
may be associated with modulation of p68 phosphorylation.
Ras oncogene activation in human thyroid tumours
Binding of ligands to the 55kD component of the interleukin-2
receptor triggers generation of cyclic AMP
A.R. Mire-Sluis, A.V. Hoffbrand & R.G. Wickremasinghe
Department ofHaematology, Royal Free Hospital School of
Medicine, Pond Street, London NW3 2QG, UK.
The receptor for interleukin-2 (IL-2) consists of two non-
sulfhydryl linked transmembrane glycoproteins of 55 and
75kD. Mitogenic activation of T lymphocytes requires the
formation of a ternary complex between IL-2 and both the
receptor components. We have investigated aspects of the
mechanism of transduction of the IL-2 proliferative signal.
Binding of IL-2 to its receptor triggers transient generation
of cyclic AMP (cAMP). The monoclonal antibody antiTac
binds only the 55kD receptor component, is not mitogenic
and can block the mitogenic action of IL-2. AntiTac also
stimulates generation of cAMP. When permeabilized
lymphocytes were incubated with [y-32P]ATP both IL-2 and
antiTac rapidly stimulated phosphorylation of an 85 kD
protein (p85). p85 phosphorylation was also stimulated by
addition of cAMP, but not of cGMP or of a protein kinase
C activating phorbol ester. We therefore suggest that ligand
binding to the 55 kD component of the IL-2 receptor triggers
cAMP generation, which activates the cAMP-dependent
kinase system, leading to phosphorylation of p85. However,
because antiTac is non-mitogenic, other biochemical
pathways triggered by ligand binding to the 75kD receptor
component must also be involved in securing commitment of
lymphocytes to mitosis.
N.R. Lemoine, F.S. Wyllie, V. Wynford-Thomas &
D. Wynford-Thomas
Cancer Biology Unit, Department ofPathology, University of
Wales College ofMedicine, Cardiff, UK.
The presence of activated oncogenes in human thyroid
cancer was investigated by transfection of genomic tumour
DNA into untransformed NIH3T3 mouse fibroblasts.
Fibroblast transformation was detected: (a) by the
occurrence of dense foci in monolayer, and (b) by the
development of tumours in nude mice within 8 weeks after
injection (after initial selection for a co-transfected genetic
marker).
Five follicular and 11 papillary carcinomas were studied.
In only 1 case (a follicular tumour) was transformation
detected by the focus assay. In contrast, using the nude
mouse assay, all 5 follicular, and 10 of the 11 papillary cases
showed transforming activity. No tumours were observed in
control transfections using normal mouse or human DNA.
DNA from all nude mouse tumours was positive for trans-
forming activity both by focus induction and nude mouse
tumorigenesis in second and third rounds of transfection,
usually with higher efficiency.
Southern analysis of DNA of transformants derived from
follicular cancers identified a human Ha-ras gene in 2 cases,
N-ras in 1 case and Ki-ras in 1 case. Oligonucleotide probing
demonstrated point mutations in each case involving Ha-ras
(codon 61 Gln-.Arg) and N-ras (codon 61Gln-.His), and is
in progress for Ki-ras. Corresponding analysis for the
papillary cancer identified N-ras in one and Ki-ras in a
second case (Ha-ras was not identified in any). Oligo-226 JOINT MEETING OF THE BACR, THE CRC AND THE ICRF
nucleotide probing demonstrated a point mutation at codon
61, position 2 in the Nras oncogene.
Human thyroid cancer therefore shows a surprisingly high
incidence of transforming activity, and in the case of the
follicular type, a high incidence of ras oncogene activation.
Met-encoded protein phosphorylation in human tumour-derived
cell lines
P.R. Tempest & C.S. Cooper
Institute ofCancer Research, Fulham Road, London
SW3 6JB, UK.
The met gene present in the transformed human cell-line
MNNG-HOS is activated by a chromosomal translocation in
which the 5' region of the met gene (located on chromosome
7) is replaced by promoter sequence derived from an
unrelated gene located on chromosome 1. Sequence analysis
of cDNA clones indicates that met most likely encodes a
receptor for an as yet unidentified growth factor. In order to
examine proteins encoded by the normal and activated met
genes we have raised antisera against a synthetic peptide
corresponding to the carboxyl terminus of the predicted met
gene product. The antipeptide antibodies have enabled us to
show that the activated met gene encodes 60 and 65kD
polypeptides that when incubated in vitro in the presence of
ATP and Mn2+ can catalyse autophosphorylation on
tyrosine residues. These studies also provide evidence that
the normal unrearranged met gene, present in the parental
HOS cell line, encodes 140 and 165kD polypeptides that can
catalyse autophosphorylation.
To determine whether activation of met can be implicated
in the induction of human tumours we have used the in vitro
protein kinase assay to screen human tumour cell lines for
alterations in the product of the met gene. Using this assay
we have identified altered met protein kinase activity in cell
lines from two cervical carcinomas, a medulloblastoma and a
lung carcinoma. Some of these cell lines possess abnormally
high levels of kinase activity of the 140kDa polypeptide
while others exhibit alterations in the size of the met gene
product. In future studies we hope to discover the
significance of these alterations in the product of the met
gene.
Ras replaces TPA requirement for growth, and induces
tumorigenicity, in murine melanocytes
R.E. Wilson, T. Dooley & I.R. Hart
Imperial Cancer Research Fund Laboratories, Lincoln's Inn
Fields, London WC2A 3PX, UK.
Recently we isolated an immortal line of non-tumorigenic
melanocytes requiring the presence of 12-0-tetra-decanoyl
phorbol-13-acetate (TPA) for continuous growth (Bennett et
al., Int. J. Cancer, 39, 414, 1987). A variant (Mel-ab) of this
line has been transfected with various plasmids containing
both the aminoglycoside phosphotransferase gene and
activated cellular Ha-ras or viral Ha-ras genes.
Transfectants, isolated on the basis of their resistance to
G418 (800pgml-1), were examined for in vitro growth
characteristics and tumorigenic capacity. Untransfected cells,
or control transfectants lacking the ras gene, only grew in
the presence of 150-200nM TPA. In contrast, cells (Mel-ab
pAGT) containing activated cellular Ha-ras under transcrip-
tional control of the herpes simplex virus Tk gene grew
equally well in the absence or presence of TPA. Moreover,
cells containing the viral Ha-ras gene under control of a
retroviral LTR (Mel-ab LTR ras) not only grew well in the
absence of TPA but were actually growth inhibited by the
addition of TPA (160nM). The cAMP elevating agent
cholera toxin (ct) at 10 9M failed on its own to stimulate
proliferation but acted synergistically with TPA to induce
mitogenesis in untransfected Mel-ab cells. In contrast Mel-ab
LTR ras cells responded strongly to 10 -9M ct alone, though
this proliferative effect was abrogated completely by TPA.
Tumorigenicity of the various cell lines was monitored by
injecting suspensions of viable cells s.c. into thymic, nude
mice. Mel-ab cells (2 x 106) failed to produce tumours even
after 200 days, whereas 5 out of 5 animals injected with
1 x 106 Mel-ab pAGT or Mel-ab LTR ras cells grew >1 cm
diameter tumours in less than 20 days. Histological
examination and specific stains showed that these tumours
were malignant melanomas.
These results show that ras-induced tumorigenicity is
associated with the induction of autonomous growth.
A mediating role for topoisomerase II in oestrogenic
recruitment of human breast cancer cells
R.J. Epstein', J.P. Moore2, G.I. Evan2 & P.J. Smith'
1MRC Unit, Clinical Oncology and Radiotherapeutics, and
2Ludwig Institutefor Cancer Research, MRC Centre, Hills
Road, Cambridge, UK.
Several studies have associated mitogenic activation with a
rise in extractable cellular topoisomerase II activity which
parallels stimulation of DNA synthesis. Using auto-
radiography we have shown that oestrogenic stimulation of
DNA synthesis in T-47D cells first becomes detectable after
16h exposure, and that 15-20% more cells are recruited into
DNA synthesis by 24h. Enhancement of drug-induced
topoisomerase-II-mediated DNA cleavage by oestrogen is
not, however, antagonised by inhibition of DNA synthesis
using aphidicolin or hydroxyurea. Stimulation of c-myc
protein synthesis is maximal within 1-2h of oestrogen
exposure, while elevations in topoisomerase-II-mediated
DNA cleavage, cellular topoisomerase II content, and
extractable topoisomerase II activity are readily detectable
within 4h of stimulation. No enhancement of topoisomerase-
mediated DNA cleavage is seen following inhibition of
poly(ADP-ribosyl)ation with 3-aminobenzamide. Flow
cytometry confirms that oestrogen stimulation is associated
with increased topoisomerase II content in a GI-phase cell
subset. These findings suggest (1) that drug-induced
topoisomerase-IT-mediated DNA cleavage is a useful monitor
of enzyme:DNA interaction in intact cells; (2) that oestrogen
enhances topoisomerase II synthesis in an activated Gl-
phase cell subset; and (3) that topoisomerase II may play a
controlling, rather than a facilitating, role in chromatin
activation.
Cyclical expression of oestrogen receptor in normal breast
epithelial cells does not occur in breast cancer
C. Markopoulos" 2, U. Berger2, J.-C. Gazet', P. Wilson &
R.C. Coombes" 2
1Combined Breast Clinic, St George's Hospital, Blackshaw
Road, London SWJ7 OQT, and Ludwig Institutefor Cancer
Research, St George's Hospital Medical School, Cranmer
Terrace, London SWJ7 ORE, UK.
We have used a monoclonal antibody (H222) to the
oestrogen receptor (ER) to identify receptor in cytological
samples obtained by fine needle aspiration (FNA) from
women with normal breasts throughout the menstrual cycle.
We have also examined biochemically (DCC) ER content of
breast cancers in relation to the time in the menstrual cycle
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In normal premenopausal women ER was detected in the
nuclei of epithelial cells in 21/68 (31%) assessable samples,
all of which were obtained from women during the first half
of their menstrual cycle (days 28 to 14). No sample obtained
during the second half of the cycle contained ER.
Analysis of ER content of 83 carcinomas in relation to the
menstrual day during which excision was performed showed
equal distribution of the ER positive cases throughout the
menstrual cycle.
The results of this study on normal breast epithelial cells
indicate that ER protein production is suppressed at the time
of ovulation in the normal breast epithelium of pre-
menopausal women. In contrast, breast carcinoma cells
either synthesise this protein continuously throughout the
cycle or fail to express it despite fluctuationrs of serum
hormones.
Correlation of progesterone receptor immunohistology with
radioligand-binding assay and oestrogen receptor
immunohistology in breast carcinomas
D. Giril, J. Goepell, K. Rogers2 & J. Underwood1
Departments of 'Pathology and 2Surgery, University of
Sheffield Medical School, Sheffield S1O 2RX, UK.
Radioligand-binding assays for progesterone receptor (PR)
suffer disadvantages similar to those described for oestrogen
receptor (ER) assays. We therefore evaluated immuno-
staining by a monoclonal antibody to PR by comparison
with radioligand-binding assay for PR as well as ER
monoclonal immunohistology on adjacent cryostat sections
to minimise sampling differences arising from tumor hetero-
geneity. Of the 103 samples studied 37 (36%) and 66 (64%)
showed significant nuclear staining with the PR and ER
monoclonal antibodies respectively. The immunohistological
results showed close correlation with the respective
biochemical assays (P<0.0001). Further the monoclonal
antibody study showed that 34 of the 66 cases immuno-
histologically regarded as ER positive were PR positive,
whereas significantly 3 of the 37 deemed as low positive or
negative for ER showed strong expression of PR with
concordant biochemical assay results. This suggests that in a
small number of breast carcinomas constitutive differences
may account for PR expression independent of ER. The
study clearly shows that nuclear staining by this monoclonal
antibody to PR (as previously established for ER (Giri et al.,
J. Clin. Pathol., 46, 734, 1987)), correlates strongly with
biochemically assayed PR values and appears to be an
acceptable alternative to such assays currently favoured in
clinical practice. The immunohistological method advan-
tageously identifies, in addition, both the occupied and
unoccupied receptor sites and reveals intratumoral cell-to-cell
and regional heterogeneity for ER.
Detection of tumour cells in bone marrow of patients with
prostatic carcinoma by immunocytochemical methods
J. Mansi" 2, U. Berger', P. Wilson1, R. Shearer2 & R.C.
Coombes",2
'Ludwig Institutefor Cancer Research, St George's Hospital
Medical School, London SW17 ORE, 2St George's Hospital,
London SW17 OQT, UK.
We have used a cocktail of antisera to prostatic specific acid
phosphatase, prostatic specific antigen, epithelial membrane
antigen and cytokeratin to examine multiple bone marrow
aspirates from pateints with local (n = 15) and metastatic
prostatic carcinoma (n = 15) and benign prostatic hyper-
trophy (n = 10). We found moderate to large numbers of
tumour cells in the bone marrow of 11 of 15 (73%) patients
with known metastatic disease, and small numbers of
abnormal cells in 2 of 15 (13%) patients with apparently
local disease. No tumour cells were found in patients with
benign prostatic hypertrophy, and only two patients with
metastatic disease were found to have tumour cells in their
bone marrow when conventional haematomorphological
preparations were examined.
These findings suggest that immunocytochemistry can
increase the detection rate of metastatic prostatic carcinoma
cells. Further follow-up of larger numbers of patients with
local carcinoma will reveal whether the presence of micro-
metastases denotes a poor prognosis.
The significance of intratumoral aromatase[A] (oestrogen[E]
synthetase) in human breast cancer[BC]
M. Cunha e Silva', M.G. Rowlands2, M. Dowsett3,
U. Berger', E.R. Simpson4, C.R. Mendelson4, I. Fraytt5 &
R.C. Coombest
'Ludwig Institutefor Cancer Research, St George's Hospital
Medical School, London SW17 ORE, 2Institute of Cancer
Research, Sutton, Surrey, 3Chelsea Hospitalfor Women,
London SW3, 4University Medical School, Dallas, USA,
5Royal Marsden Hospital, London SW3, UK.
A proportion of BC depend on E2 for their continued
proliferation. Although E2 originates in part from ovarian
and adipose tissues, tumour-synthesised E2 by intratumoral
A could also be important because of the proximity of this
source of E2. In order to determine the significance of
intratumoral E2 production we have measured the A content
of 114 primary BC removed between 1981 and 1986 using
the tritiated water-release assay which measures %
conversion of precursors to E2 (interassay variation 5%).
46/114 (40%) % of <0.02% conversion, 48/114 (42%) %
conversion of 0.02-0.09% and 20 (18%) showed conversion of
>0.09%. There was no relationship between A content and
tumour size, histological type, nodal status or ER status. We
also examined the relationship between A content and
relapse, since 60% of patients have developed overt distant
metastatic disease over this period. However, there was no
relationship between rate of relapse and A content since 5 yr
relapse rate was 65% (<0.02%), 50% (0.2-0.09%) and 45%
(>0.09%) (P=NS).
In order to localise the enzyme activity more accurately we
have utilised monoclonal and polyclonal antisera to A and
excellent localisation occurs in ovary and placenta. Some
staining is seen in BC tissue but predominantly in stromal
cells.
In conclusion, intratumoral E2 production by breast
cancer appears unrelated to ER or other prognostic indices
and is not a determinant of prognosis. Further studies using
immunological reagents are being done to assess the signifi-
cance of tumour associated A.
Expression of cytochrome P450 and glutathione-S-transferase
isozymes in human breast tumours
L.M. Forrester', J.D. Hayes2, R.R. Millis3, L. Bobrow3,
I.S. Fentiman3, A.H. Harris4, M. Glancy' & C.R. Wolf'
'ICRF Laboratory ofMolecular Pharmacology and Drug
Metabolism, Hugh Robson Building, George Square,
Edinburgh, 2Department ofClinical Chemistry, University of
Edinburgh, Edinburgh, 3ICRF, PO Box 123, Lincoln's Inn
Fields, London, 4Department ofRadiotherapy, Newcastle
General Hospital, Newcastle, UK.
The expression of cytochrome P-450 and glutathione-S-
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of breast tumour samples. Immunoblotting shows that all
breast tumours analysed contained a cytochrome P-450 form
associated with the P-450 C2C locus. Isozymes within this
locus appear to be invovled in steroid hydroxylations which
may relate to hormone homeostasis with the tumour and the
metabolism of drugs such as tamoxifen. The metabolism of
7-ethoxyresorufin (a marker substrate for P-450 C2C) could
also be detected in these tumours. Other cytochrome P-450s
analysed within the P-450 C2A, P-450 C2B and P-450 Cl
loci were not detected in these samples. All breast tumour
samples analysed expressed high levels of the acidic (A) GST
isozyme a protein which has been associated with drug
resistance. This could have important implications in their
sensitivity to anti-cancer drugs. Variable levels of the neutral
(u) GST isozyme were present in the different tumours. It
was intriguing that the basic subunit was only detected in 1
out of 14 samples tested. The activity of glutathione-S-
transferase substrates 1-chloro-2,4-dinitrobenzene, ethacrynic
acid (acidic) and cumene hydroperoxide (basic) as well as
glutathione peroxidase activity have been compared to the
GST isozyme content and where possible to the histological
sub-type and clinical response to therapy.
Effect of long-acting somatostatin analogue on the growth of
human lung cancer cell lines
V.M. Macaulay, M.J. Everard, G.P. Joshi, I.E. Smith &
J.L. Miller
Institute ofCancer Research and Lung Unit, Royal Marsden
Hospital, Sutton, Surrey, UK.
Lung cancer cells secrete peptide factors which may
contribute to autonomous tumour growth. Bombesin is
synthesised by and mitogenic to many small cell lung cancer
(SCLC) cell lines (Carney et al., Cancer Res., 47, 821, 1987).
We have shown synthesis of insulin-like growth factor-I
(IGF-I) by most SCLC and non-SCLC tissues and cell lines.
We examined the effects on human lung cancer cell lines of
an inhibitor ofpeptide secretion. The long-acting octapeptide
somatostatin analogue sandostatin was tested on 3 SCLC
and 3 non-SCLC lines. The assay system measured 3H-
thymidine uptake by cell suspensions in unsupplemented
RPMI medium. Two of the 3 SCLC cell lines synthesise and
secrete detectable levels of bombesin and IGF-I. However
sandostatin 0.0O1-lOOOngml-' (10-12-106M) had no signi-
ficant effect on DNA synthesis by these lines. None of
the 3 non-SCLC lines produce bombesin, but IGF-I is
detectable in 2 (NCI-H125, adenocarcinoma; NCI-H226,
squamous). NCI-H226 showed inhibition of 3H-thymidine
uptake to 68+6% of control levels (P<0.01) in response to
sandostatin 1000ngml- . We also saw an effect in one of the
2 adenocarcinoma lines, NCI-H23. There was significant
inhibition (89±0.5%, P<0.05) even at the lowest drug
concentration; the effect was maximal at 1000ngml'1
(79+4%, P<0.01). In the presence of 10% serum we were
unable to show activity in any line. Thus we have demon-
strated only modest effects in 2 of 3 non-SCLC but 0 of 3
SCLC cell lines. There was no correlation between response
and synthesis/secretion of bombesin or IGF-I. Growth factor
secretion may not be a prerequisite for receptor binding and
activation. We plan to assess the effect of sandostatin on
serial peptide secretion, and to alter drug schedules to
maximise growth inhibition.
Chemotherapy for malignant melanoma: Improved response
without survival benefit
S. Lakhani, P. Selby, J.M. Bliss, M. Cornbleet, M. Mbidde
& T.J. McElwain
Sections ofMedicine and Epidemiology, Institute ofCancer
Research and Royal Marsden Hospital, Sutton, UK.
We have carried out a retrospective analysis of 164 patients
(pts) with recurrent melanoma seen at the Royal Marsden
Hospital between 1976-1986 who had received no previous
chemotherapy. They received one of four chemotherapy
regimens: Vindesine (VDN) 3mgm-2 weekly (80pts),
melphalan (HDM) 200mgm-2 with autologous bone
marrow transplantation (ABMT) (34pts), BCNU
(HDBCNU) 800mg m-2 with ABMT (9pts) and BOLD
regimen (bleomycin, vincristine, CCNU, DTIC) (41 pts). The
groups were similar in their age, sex and clinical charac-
teristics. The indications for chemotherapy were progressive
disease or uncontrolled symptoms, usually pain. The
response to treatment was evaluated using the WHO criteria.
The response rates (CR+PR) for the four treatment
schedules were: VDN 2.5%, HDM 20.6%, HDBCNU 44.4%
and BOLD 24.4%. Although the response rates for HDM,
HDBCNU and BOLD were significantly higher (P<0.005)
than that for VDN, there was no evidence of prolonged
survival with any of the chemotherapy regimens and the
choice of treatment was not a significant predictor of survival
on multivariate analysis, although responders lived longer
than non-responders as usual. Toxicity was predictably
greatest with high dose and combination chemotherapies.
The results are disappointing. High dose and combination
chemotherapy can improve response rates but there are few
complete remissions and the increase in partial remissions
does not seem to improve survival in this disease. It seems
probable that only a treatment which produces complete
remissions is likely to do this.
Platelet derived growth factor and insulin-like growth factor II
expression in human breast biopsies
M.T. Travers, P.J. Barrett-Lee, Y. Luqmani & R.C.
Coombes
Ludwig Institutefor Cancer Research, St George's Hospital
Medical School, Cranmer Terrace, London SW17 ORE, UK.
The levels of mRNAs for platelet-derived growth factor
(PDGF) A and B chains and insulin-like growth factor II
(IGF-II) known to be secreted by some human breast cancer
cell lines, and to stimulate proliferation of mesenchymal cells
in vitro, were examined in 51 malignant and 19 non-
malignant human breast biopsies by northern and dot blot
analysis using human cDNA probes. PDGF-A and B chain
transcripts were found in all normal and benign tissue
examined. All tumours studied contained PDGF-A
transcripts (38/38) and 33/37 (89%) possessed detectable
mRNA for the PDGF-B chain. Variations in the levels of A
and B chain transcripts were observed in 26 malignant and 8
non-malignant breast samples suggesting a lack of co-
ordinated expression of these factors. However, the levels of
these transcripts found in lymph node metastases from 5
patients were similar to those found in their respective
primary tumours. PDGF-A and B chain expression was also
found to be unrelated to oestrogen receptor protein levels.
Northern analysis showed a single 4kb PDGF-B chain
transcript and three bands of 2.9, 2.4 and 1.8kb for PDGF-
A. IGF-II transcripts of sizes 6 and 4.8kb were abundant in
all normal and benign tissues (15/15) and were present, but
at much lower levels in 11/21 (52%) of carcinomas. The level
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carcinomas and showed no relationship to the level of A
and/or B chain transcripts. The association of IGF-II
message with normal and benign tissue may reflect a role for
this growth factor in promoting the proliferation of stromal
elements. Alternatively stromal cells may themselves secrete
this growth factor. Studies involving in situ hybridisation of
benign and malignant tissue sections may help to resolve
these questions.
PDGF and TGF-B influence proliferation of and extracellular
matrix production by mouse embryonic palatal mesenchyme
cells in vitro
P.M. Sharpe, M.J.M. Carette & M.W.J. Ferguson
Department ofCell and Structural Biology, University of
Manchester, UK.
Mammalian palatogenesis involves the differentiation of
epithelia from 3 regions of the palate (oral, nasal and
medial edge), into specific phenotypes. This differentiation is
directed by the underlying mesenchyme (Ferguson & Honig,
Curr. Top. Develop. Biol., 19, 137, 1984). Immunocyto-
chemical and proliferative studies on mouse embryonic
palatal mesenchyme (MEPM) cells were undertaken to
elucidate molecular controls of mesenchyme signalling.
Extracellular matrix (ECM) deposition and proliferation
were compared when cells were cultured on various substrata
(on plastic, on collagen gel and in collagen gel), in response
to DMEM/F12 medium supplemented with donor calf serum
with or without platelet derived growth factor (PDGF) and
transforming growth factor beta (TGF-B). PDGF elicited
substrate specific mitogenic responses; stimulation on plastic,
no effect on collagen and inhibition within collagen gel
matrices. TGF-B exerted inhibition of cell growth irrespec-
tive of culture substratum. Immunocytochemical localisation
of collagen types I, III, IV, V, IX, fibronectin, laminin,
tenascin and heparan sulphate proteoglycan when MEPM
cells were cultured on glass or collagen film substrata in the
presence of absence of PDGF and TGF-B indicated that
with TGF-B present collagen types III, IV, V, fibronectin
and laminin were qualitatively more abundant. PDGF had
no apparent effect with the exception of an increase in type
III collagen production. These results implicate regulatory
roles for both PDGF and TGF-B during palate development.
Differential effects of TGFfi on normal and neoplastic
hepatocytes
B.I. Carr, R.D. Whitson, T. Fielder, H. Hoshi & K. Itakura
City ofHope National Medical Center, Duarte, CA 91010,
and W. Alton Jones, Cell Science Center, Inc., Lake Placid,
NY 12946, USA.
TGFf is a potent non-toxic inhibitor of mitogen-induced
DNA synthesis in primary cultures of adult rat hepatocytes
(Cancer Res., 46, 2330, 1986). Since TGFfl gene expression
occurs in rat liver, we investigated whether a variety of
human and rat hepatomas differed from normal hepatocytes
in response to the inhibitory actions of TGF/. Hepatocytes
or hepatoma cell lines were culture in serum-free medium for
24h with TGFB 0-10ngmlP-. The medium was then
changed to fresh medium containing growth factors
(hepatocytes) or foetal calf serum (hepatomas) without
TGF,B. DNA synthesis was assessed 72-96h later (normal
hepatocytes) or growth curves were measured over the
subsequent days (hepatomas). Normal human foetal hepato-
cytes were similar to rat hepatocytes in the dose responsive-
ness to the inhibitory actions of TGFP with an ID50 of
0.5ngml-'. Growth curves on rat hepatomas H-4-II-E,
RH7777 and HTC, and human hepatomas HEP G2,
PRC/PRF/5, HEP 3B. HuH-7 and SK-HEP-1 showed no
inhibition of growth at any of the tested doses except for
HEP 3B and HuH-7 which showed 50% inhibition at
lOngml-PTGFf. The binding of 125I-TGFfl was measured
on all hepatocyte cell lines. The hepatomas had between
150-800% of the binding of normal rat hepatocytes,
measured over 4h at 4°C. Affinity cross-linking gels showed
at least 4molwt species of TGF10 receptor. The hepatoma
cell lines produced a factor(s) in their medium which caused
a > 10-fold increase in DNA synthesis when tested on
normal rat hepatocytes and completely antagonized any
inhibitory effects of TGF#. This endogenously-secreted
growth stimulant may be important in the resistance of
hepatomas to the growth inhibitory action of TGF/.
Decreased sensitivity of hepatocytes from regenerating rat liver
to the growth inhibitory action of transforming growth factor 0
A.J. Strain, D.J. Hill & R.D.G. Milner
Department ofPaediatrics, Clinical Sciences Centre, Northern
General Hospital, Sheffield S5 7AU, UK.
Transforming growth factor f (TGFJ) is a potent reversible
inhibitor of DNA synthesis in adult rat hepatocytes in vitro.
Our previous work has shown that TGFP inhibits DNA
synthesis in hepatocytes isolated from normal liver and from
regenerating liver 18h following partial hepatectomy with
equal potency (Strain et al., Biochem. Biophys. Res. Com., 45,
436, 1987). In the present study, the response of hepatocytes
from 3h, 6h and 12h regenerating liver was determined.
Hepatocytes were isolated by collagenase perfusion and were
maintained in serum-free William's E medium for up to 5
days. Medium with or without growth factors was
replenished daily and [3H]-thymidine added for the final 24h
ofculture.
TGFP inhibited DNA synthesis uniformly in hepatocytes
from normal liver and from 3h, 6h and 12h regenerating
liver in the absence of epidermal growth factor (EGF).
However, cells from 3h and to a lesser extent from 6h
regenerating liver maintained in the presence of 0.85nM EGF
for 72h were less sensitive to the growth inhibitory action of
TGFf. [3H]-thymidine incorporation was inhibited at 20pM
TGF,B by only 7% and 33% in hepatocytes from 3h and 6h
regenerating liver respectively compared with 70% in normal
hepatocytes. No change in sensitivity was observed in cells
from rats following sham hepatectomy. Within a further 24-
48h, TGFfi inhibited DNA synthesis by a similar degree in
hepatocytes from 3h regenerating liver in the presence or
absence of EGF. These data are compatible with the
hypothesis that TGF,B plays a role as a paracrine growth
regulator in adult rat liver. Thus, following partial
hepatectomy a transient decrease in sensitivity of hepatocytes
to the growth inhibitory action of TGF,B would result in
release of cells from growth restraint.
The effect of a-interferon (a-IF) on TGF-p cellular mRNA
levels in human breast cancer cells in vitro
D.J. Kerr1, A. Sproul4, S. Cowans3, W.D. George3, R.D.
Leake3 & I.B. Pragnell4
Departments of'Medical Oncology, 2Surgery and
3Biochemistry, Glasgow University, and 4Beatson Institutefor
Cancer Research, Glasgow, UK.
Transforming growth factor-f (TGF-,B) has an anti-
proliferative effect on epithelial tumour cell lines in vitro and
may have a role in the regulation of growth of oestrogen
receptor positive (ER+ve) breast cancer cells by tamoxifen.
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In this study the effect of cx-IF (Kirby-Warrick) on the rate of
proliferation, phenotypic expression of ER and cellular levels
of TGF-f mRNA was determined for ER+ve breast cancer
cells (ZR-75 line). Continuous exposure of exponentially
growing cells to a-IF (500IUml-') significantly increased
cell doubling time from 23.2 to 42.5h (P<0.05). Approxi-
mately 12h after initial treatment with ot-IF, ER levels had
fallen to 15-20% of control values (P<0.05) and stayed at
this reduced level in the presence of a-IF. RNA was phenol
extracted from exponentially growing cells and TGF-#
mRNA levels were assessed by standard dot hybridisation
with a cDNA probe specific for TGF-,B. 24h following a-IF
treatment, TGF-f mRNA had risen by approximately 5-10
fold relative to control and was maintained at this elevated
level until a-IF was removed from culture medium.
Preliminary studies indicate that for TGF-# has an anti-
proliferative effect on ZR-75 cells and it is possible that the
cytostatic effect of x-IF is mediated by variation in
phenotypic expression of ER and TGF-/3.
The trophic effects of gastrin on the human gastric cell line,
MKN45 in vitro and in vivo
S.A. Watson', L.G. Durrant' & D.L. Morris2
'Cancer Research Campaign Laboratories, University of
Nottingham NG7 2RD, and 2Department ofSurgery,
University Hospital, Nottingham NG7 2UH, UK.
The recent evidence that the hormone, gastrin, stimulates
growth of gastrointestinal tract tumour cells was further
investigated.
The established human gastric cell line, MKN45, was
evaluated for the presence of gastrin receptors by flow
cytometry and found to have a definitive number. MKN45
showed no in vitro growth response to gastrin as measured
by 75[Se] selenomethionine incoporation unless thymidine
synchronisation of the cell population was induced after
which the cells responded trophically (125% of control) to
gastrin.
The same cell line was xenotransplanted into nude mice,
the resultant tumours were disaggregated and placed in in
vitro culture where upon synchronisation they showed an
even greater trophic response to gastrin (145% of control),
but this response was lost on further passaging.
Such xenotransplants were examined for gastrin-
dependence in vivo and 50-60% of the tumours responded
trophically to exogenous gastrin. When the gastrin
responsive tumours were retransplanted an overall increase
in growth and a greater response to gastrin was achieved
with gastrin-treated tumours reaching a median weight of
1.0g, 7 days before corresponding saline-healed tumours.
The overall response to gastrin was further improved by
administering the compound continuously via a pump.
It is suggested that gastrin receptor antagonists may have
a future role in the inhibition of gastric and colorectal cancer
growth.
Growth inhibition by neurotensin in small cell lung cancer cell
lines in vitro
J.G. Reeve, J.J. Shaw & N.M. Bleehen
Clinical Oncology and Radiotherapeutics Unit, MRC Centre,
Hills Road, Cambridge, UK.
Selected human small cell lung carcinoma (SCLC) cell lines
contain high levels of neurotensin but fail to express specific
cell surface neurotensin binding sites (Goedert et al., Br. J.
Cancer, 50, 179, 1984), suggesting that unlike bombesin, this
peptide has no autocrine mode of action in these cells. To
investigate this possibility, neurotensin was added to SCLC
cell lines growing in vitro in HITES medium, at concen-
trations ranging from 50nm to 5pM. Cells were counted at
intervals during a 7-10 day period. Among the 8 SCLC cell
lines (6 'classic'; 2 'variant') neurotensin exhibited dose-
dependent anti-proliferative activity. This effect was also seen
in a large cell lung carcinoma cell line and in a breast
carcinoma cell line. Experiments carried out in RPM1
containing 10% fetal calf serum showed a significant but
reduced anti-proliferative effect for neurotensin. Structure-
activity studies indicated the importance of COOH-terminal
structures as determinants of specific neurotensin binding
and biologic action. To date partial NH2 terminal sequences
including NT1-10 have no known physiological effects.
However, when NH2- and COOH-terminal fragments were
assessed for anti-proliferative effects on SCLC cell lines, both
were found to be of similar potency as the complete peptide
at equimolar doses. These observations, together with the
lack of detectable neurotensin binding sites on several of the
SCLC cell lines used in this study, indicate that the growth
inhibitory action of neurotensin is not mediated via inter-
action with specific, high affinity neurotensin receptors.
A potent bombesin antagonist [DArg',DPhe5,DTrp7'9,Leull]
substance P, inhibits the growth of human small cell lung
carcinoma (SCLC) in vitro
P.J. Woll & E. Rozengurt
Growth Regulation Laboratory, Imperial Cancer Research
Fund, London WC2A 3PX, UK.
Bombesin-like peptides are secreted by many SCLC and may
act as autocrine growth factors for these tumours. We have
demonstrated that [DArg',DPhe5,DTrp7,9,Leu' ] substance
P (D) is a potent bombesin/gastrin-releasing peptide (GRP)
antagonist in mouse fibroblasts (Swiss 3T3 cells) which (i)
inhibits DNA synthesis stimulated by GRP; (ii) blocks
[125I]GRP binding to the GRP receptor; (iii) reduces cross-
linking of the Mr 75000-85000 protein putatively a com-
ponent of the bombesin/GRP receptor; (iv) blocks some of
the early cellular events which precede mitogenesis. D also
inhibits mitogenesis stimulated by vasopressin, but not that
induced by a variety of other growth factors. D is 5-fold
more potent than the previously described bombesin
antagonist [DArg',DPro5,DTrp79 9,Leu'1l] substance P (A).
SCLC cell lines maintained in serum-free medium (RPMI
1640 with hydrocortisone, insulin, transferrin, estradiol,
selenium and bovine serum albumin) achieve 10-fold growth
in number in about 10 days. The growth of three cell lines
was markedly retarded in the presence of A, but could be
restored by changing the medium. Both A and D inhibit the
growth of SCLC in a concentration-dependent manner, and
again D is 5-fold more potent than A. Non-SCLC cell lines
are relatively unaffected by D. More potent and specific
peptide antagonists of GRP could have therapeutic
applications.
Enhancement of angiogenesis by interleukin-l: Quantitative
studies using a rat sponge model
T.-P.D. Fan', S.P. Andrade' & J. Saklatvala2
'Department ofPharmacology, University ofCambridge,
Cambridge CB2 2QD, and 2Strangeways Research
Laboratory, Cambridge CBJ 4RN, UK.
Tumour angiogenesis is an important control point in the
growth of solid tumours. Knowledge about the precise
stimulus for such neovascularisation and its mechanism of
action will therefore offer clues for immunopharmacologicalJOINT MEETING OF THE BACR, THE CRC AND THE ICRF 231
strategies in cancer treatment. Recent studies have shown
that polypeptide growth factors such as fibroblast growth
factor (FGF) and transforming growth factor (TGF)
stimulate the growth of new blood vessels (see Folkman,
NIPS, 1, 199, 1986). We report here that interleukin-l (IL-1)
may also be an angiogenic factor. The method (Andrade et
al., Br. J. Exp. Path., 68, 755, 1987) is based on sub-
cutaneous implantation of sterile polyester sponges in rats
and subsequent measurement of blood flow in the implants
as they become vascularised. Saline, vehicle control or
different concentrations of IL-1 in lOO1 uI was injected into
the sponge via an attached cannula. Histological studies of
implants removed at fixed time intervals confirmed that the
sponges were gradually infiltrated by host blood vessels. The
blood flow in an implant was measured in terms of 133Xe-
saline clearance 6min after the radioisotope was injected into
the sponge via the cannula. Under standard conditions, the
133Xe clearance from control sponges 16 days post-
implantation approached the clearance obtained in normal
skin. However, 5ng of porcine IL-lx (Saklatvala et al., J.
Exp. Med., 162, 1208, 1985) caused accelerated angiogenesis
10+1 days post-implantation. Higher doses (20, 50ng) of
IL-1 were also effective, though there were no significant
differences between the three test groups. Further work to
assess the relative contribution of IL-1, FGF, TGF and other
growth factors in this model of angiogenesis is underway.
Growth factor-induced angiogenesis determined by a new in
vivo assay
V. Mahadevan'2, I.R. Hart2 & G.P. Lewis
1Department ofPharmacology, Royal College ofSurgeons,
2Imperial Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK.
The angiogenic activities of a number of purified growth
factors have been determined using a novel in vivo assay,
first described by Andrade et al. (Br. J. Exp. Path., 68, 755,
1987). A sterile polyether polyurethane sponge disc
(1.25cm x 0.6cm) with an attached polyethylene cannula
(1 cm long) was implanted into the dorsal subcutaneous
tissues of groups of young adult Wistar rats. Since clearance
of radiolabelled xenon can be used to measure blood flow
(Sjersen, Circ. Res., 25, 215, 1969; Fan & Lewis, Br. J.
Pharmacol., 74, 964, 1981) progressive vascularisation of the
sponge was assessed by injecting 10p1 of Xenon133 solution
(370MBq in 3ml specific activity) into the cannula then at
various times monitoring clearance rates using a collimated
y-detector placed directly over the implanted sponge.
Standard clearance curves from controls (PBS only) were
compared with those from rats receiving (1) TGF-a; 3pg on
day 7 after implantation, (2) IL-lIa; 4.8pg/day on days 7, 8, 9
and 10 or (3) TNF-oc; 5pg/day on days 7, 8, 9 and 10.
At these doses TGF-c and IL-lo were strongly angiogenic
with, for example, nine-minute Xe133-clearance values on day
12 post-implantation of 56.8%±1.6s.e. and 49.5%+±0.75s.e.
respectively versus 25.4%+ 1 s.e. for controls (P.0.001
Student's t test) while TNF-cx (27.7%±0.89s.e.) manifested no
angiogenic capacity.
The angiogenesis assay described here is both more
humane and reproducibly quantitative than those in current
use elsewhere and can be used to determine the angiogenic
capacity of any known growth factors.
Effects of recombinant human interleukin-1 (IL-1) and
recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF) on haemopoietic tissue
in vivo and in vitro
A.L. Jones, B.C. Millar, J.G.B. Bell & J.L. Millar
Section ofMedicine, Institute ofCancer Research, Clifton
Avenue, Sutton, Surrey, UK.
IL-1 is a radioprotector in mice (Neta et al., J. Immunol.,
136, 2483, 1986). We have measured its effect on
haemopoietic recovery, as measured by spleen colony
forming units (CFU-S), in relation to total body irradiation
(TBI) and chemotherapy. IL-1 (2000U i.p. 20h before TBI
or drug) did not enhance CFU-S recovery after carboplatin,
busulphan or melphalan and indeed appeared to exacerbate
gut toxicity of melphalan, as measured by crypt survival.
However IL-1 at this dose did increase CFU-S post TBI
(assessed on day 7 post TBI) between 6 and 14 fold.
Synergistic action with other biologicals may be
important. GM-CSF (100pgkg-1 i.p. bd for 6 days starting
48h before TBI), increased CFU-S recovery 12 fold. A
combination of IL-1 and GM-CSF, administered as above,
resulted in an enhanced increase of CFU-S at 26 fold.
In vitro, using human bone marrow, the number of
granulocyte macrophage colonies (GM-CFUc) increased as a
function of GM-CSF concentration up to a maximal value
which varied between patients. IL-1 enhanced the response
of GM-CFUc to GM-CSF (P<0.06): this response was
dependent on the dose of IL-1. IL-1 alone did not stimulate
GM-CFUc. The best results were seen with GM-CSF
lOOngml-l and IL-1 320Uml-1.
We conclude that biological agents should be used in
combination and may have a role in enhancing haemopoietic
recovery after irradiation.
Preliminary studies of recombinant GM-CSF in man
S. Devereux, D. Campos Costa, J. Gribben, M.F. Spittle,
A.M. Jelliffe, A.H. Goldstone & D.C. Linch
Middlesex and University College Hospitals and the British
National Lymphoma Investigation.
This study has examined the effects of recombinant human
granulocyte macrophage colony stimulating factor (rhGM-
CSF, Immunex, USA) on haemopoietic progenitor cells and
mature phagocytes in vivo. In three patients with malignant
disease not receiving chemotherapy, GM-CSF given for 10
days caused a modest neutrophilia (230% baseline) and
monocytosis (180% baseline). In three patients with resistant
Hodgkin's disease treated by very intensive chemotherapy
and autologous bone marrow transplantation the average
time to reach 1 x 1091` white cells was 13 days and to
0.5 x109I1 neutrophils was 17 days compared to 21 and 23
days respectively in 20 previous controls treated on an
identical protocol. This suggests that rhGM-CSF stimulates
granulocytic progenitor cells in vivo and may be of value in
curtailing chemotherapy induced aplasia. Further studies are
in progress. rhGM-CSF also has effects on mature phago-
cytes in vivo. One hour infusions of rhGM-CSF in patients
with normal blood counts results in rapid transient and
profound neutropenia and monocytopenia. Radionuclide
studies showed that this was due to transient margination
predominantly within the lungs. This in vivo phenomenon is
paralleled in vitro by a rapid calcium dependent increase in
expression of neutrophil adhesion proteins and adherence to
endothelial cells. In view of this large flux of phagocytes to
the lung caution should be exercised in the administration of
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Phase I/II study of rhG-CSF in patients receiving intensive
chemotherapy for small cell lung cancer
M. Hernandez Bronchud', T.M. Dexter2, N. Thatcher' &
J.H. ScarffeI
'Department ofMedical Oncology, Christie Hospital and Holt
Radium Institute, Manchester, and 2Department of
Experimental Haematology, Paterson Laboratories,
Manchester M20 9BX, UK.
Neutropenia as a consequence of chemotherapy is probably
the most important factor responsible for increasing
susceptibility to infection in patients and hence one of the
main reasons for hospital admission during treatment. RhG-
CSF is a recombinant protein, similar to the naturally
occurring substance which increases the production of
neutrophils in man. In our study all patients have the
diagnosis of small cell lung cancer and are treated by a
combination of adriamycin 50mgm-2 i.v. bolus, ifosfamide
5gmm-2+mesna i.v. infusion (both on day 1 of each cycle)
and VP16 120mgm-' i.v. on days 1, 2 and 3. In phase I
study (prior to chemotherapy) 7 patients have so far been
studied for toxicity and effect on bone marrow (both in vitro
and in vivo parameters) of rhG-CSF administered by
continuous i.v. infusion at three different doses (1, 5 and
10ygkg-'day-'). In the phase II study the same patients
are given rhG-CSF (as before) on alternate cycles of chemo-
therapy, acting as their own control. No toxicities were
observed during the phase I part of the study - in all 7
patients the number of peripheral neutrophils increased in a
dose-dependent manner and granulocyte-function tests
proved them to be normally-functioning granulocytes.
During the phase II part of the study the period of
neutropenia was considerably reduced while on G-CSF
following chemotherapy (with a return to normal or above
normal peripheral neutrophil counts within two weeks after
day 1).
Evidence for TNF-a/cachectin production in cancer
F. Balkwill', R. Osborne3, F. Burke', S. Naylor',
D. Talbot4, H. Durbin2 & W. Fierss
'Biological Therapy Laboratory, 2Directors Laboratory,
ICRF, London WC2A 4PX, ICRF Departments ofMedical
Oncology, 3St Bartholomews Hospital, 4Homerton Hospital,
5University ofGhent, Belgium.
We have developed an ELISA assay that detects a labile
tumour necrosis factor-a, TNF-a, like activity in freshly
obtained serum from cancer patients. 50% of 226 samples
from cancer patients with active disease were positive as
compared to 3% of 32 samples from normal individuals and
18% of 39 samples from cancer patients with no evidence of
disease (P<0.0003). The activity can be absorbed from serum
by beads coated with monoclonal antibody to TNF-a. Serum
samples from patients with ovarian and oat cell carcinoma
were more frequently positive (69% and 63%) than those
patients with lymphoma (26% positive). When RNA prepara-
tions from peripheral blood mononuclear cells, PBMC, or
solid tumours, were probed with TNF-a cDNA, we found
evidence for TNF-a mRNA in 8 of 11 samples from cancer
patients but only 1 of 8 normal individuals. In addition,
TNF-cx mRNA was detected in 2 of 6 colorectal tumours.
TNF-cx may be involved in a host response to cancer, or its
production could be part of the process of tumorigenesis.
This cytokine could contribute to the symptoms and
evolution of some cancers.
The therapeutic potential of TNF-ac and its combination with
IFN-y
F.R. Balkwill', D.B. Griffin', S. Malik' & W. Fiers2
'Biological Therapy Laboratory, ICFR, London WC2A 3PX,
UK, and 2University ofGhent, Belgium.
We have studied the antitumour activity of human tumour
necrosis factor-a, TNF-cx, and human interferon-y, in human
tumour xenograft models. When a range of xenografted
cancers (breast, bowel, ovarian) were studied, TNF-a was
effective when given locally (intraperitoneally, i.p. to i.p.
tumours, intratumourally, i.t. to subcutaneous s.c. tumours)
but not systemically. Its combination with IFN-y was
additive or synergistic in the i.p. but not s.c. tumours,
resulting in a 3 fold or more increase in lifespan of mice.
The human IFN-y had no measurable effect on the nude
mouse host, but the human TNF-c caused distinctive
changes in host cell populations. Within hours of the first
injection of TNF-a there was a prominent increase in poly-
morphs i.p. and in the blood. This declined after several days
even with repeated injections but after 14-21 days of daily
therapy a pronounced lymphocytosis developed in TNF-x
treated mice. Solid i.p. tumours treated with TNF-ci showed
a marked inflammatory infiltrate and by day 3, central
necrosis. Tumour cells became replaced with collagenous
material. These changes in solid tumours were more pro-
nounced in the tumour lines that responded to TNF-a with
increased mouse survival time.
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